Previous 10 | Next 10 |
Digital Ally (NASDAQ: DGLY ) -42% on Axon patent win. More news on: Digital Ally, Inc., ContraVir Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, Read more ...
Gainers: MGI +117.9% . PHAS +14.0% . NSPR +7.4% . EIGR +4.9% . ARQL +2.7% . More news on: MoneyGram International, Inc., PhaseBio Pharmaceuticals, Inc., InspireMD, Inc., Stocks on the move, , News on ETFs Read more ...
Calithera Biosciences (NASDAQ: CALA ) announces secondary offering of 10M shares More news on: Calithera Biosciences, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Gainers: Sotheby's (NYSE: BID ) +58% . Array BioPharma (NASDAQ: ARRY ) +57% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% . Vislink Technologies (NASDAQ: VISL ) +40% . MTech Acquisition (NASDAQ: MTEC ) +34% . Endurance International Group Holdings (NASDAQ: EIGI ) +26% . C&am...
Calithera Biosciences (NASDAQ: CALA ) reports positive results from its Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). More news on: Calithera Biosciences, Inc., Healthcare stocks news, Stocks on the mo...
-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT...
NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...
Calithera Biosciences, Inc. (CALA) Q1 2019 Results Earnings Conference Call May 09, 2019, 5:00 pm ET Company Participants Jennifer McNealey - Vice President of Investor Relations and Strategy Susan Molineaux - Founder, President, Chief Executive Officer Keith Orford - Chief Medic...
Calithera Biosciences (NASDAQ: CALA ): Q1 GAAP EPS of -$0.61 misses by $0.18 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...